Market Overview
The global targeted DNA/RNA sequencing market size reached USD 13.9 Billion in 2024. It is projected to reach USD 48.1 Billion by 2033, growing at a CAGR of 14.77% during the forecast period of 2025-2033. Drivers include the rising prevalence of chronic and infectious diseases, expanding adoption of NGS technologies, and continuous technological advancements in healthcare. Targeted DNA/RNA sequencing is increasingly used in medical research for its precision, cost-effectiveness, and applicability to low concentration samples.
Study Assumption Years
• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033
Targeted DNA/RNA Sequencing Market Key Takeaways
• Market Size in 2024 was USD 13.9 Billion.
• The market is expected to grow at a CAGR of 14.77% from 2025 to 2033.
• The forecast period for the market is 2025-2033.
• The growth is driven by the increasing prevalence of chronic and infectious diseases globally.
• Adoption of solvent biopsies in cancer diagnostics is accelerating market growth.
• Expansion in genome mapping programs for diseases such as diabetes, cancer, and heart disease supports demand.
• Cloud computing integration is reducing costs and improving data management in next-generation sequencing NGS.
• Increasing demand for personalized medicine and non-invasive testing fuels market expansion.
Sample Request Link: https://www.imarcgroup.com/targeted-dna-rna-sequencing-market/requestsample
Market Growth Factors
Chronic and infectious diseases increasingly prevail globally which drives the target DNA/RNA sequencing market. Diseases globally increase. For diagnosis and treatment, diabetes, heart disease, asthma, cancer, and psychiatric disorders encourage researchers and clinicians to adopt advanced sequencing techniques. These diseases create a growing burden. Accurate sequencing is increasingly in demand to identify genetic variants linked to disease.
A large contributor to this growth is the increase in next generation sequencing technologies, which have largely been driven by the introduction of solvent biopsies and the ability to use liquid biopsy with non-intrusive cancer biomarkers such as cell-free circulating tumor DNA ctDNA for real-time monitoring and detection of cancer. This has provided a favorable environment for the adoption of targeted DNA/RNA sequencing-based methods.
Cloud computing technology will improve the ability to store and manage data and to reduce the cost of sequencing systems. Demand increases for non-intrusive testing and personalized medicine. These also expand the market’s opportunity for sequencing systems. Cooperative research and development and genome mapping programs will drive growth by providing increased understanding of the genetics of diseases.
Market Segmentation
Technology
• Next-Generation Sequencing NGS
• Others
NGS is identified as the largest segment, indicating its dominant role in the market.
Workflow
• Presequencing
• Sequencing
• Data Analysis
Sequencing accounts for the largest share, reflecting its central role in the market process.
Application
• Human Biomedical Research
• Plant and Animal Sciences
• Drug Discovery
• Others
Drug discovery is the largest application segment, highlighting the importance of sequencing in pharmaceutical development.
Type
• DNA-Based Targeted Sequencing
• RNA-Based Targeted Sequencing
DNA-based targeted sequencing holds the largest market share, showing preference for DNA-focused techniques.
End User
• Hospitals and Clinics
• Academic and Research Institutes
• Pharma and Biotech Companies
Academic and Research Institutes represent the largest end user segment, underlining their significant market involvement.
Regional Insights
North America is the largest market region for targeted DNA/RNA sequencing. This dominance is attributed to the growing prevalence of chronic diseases, rapid adoption of NGS technologies, and increased demand for personalized medicines and therapies. These factors collectively drive the region’s market growth and position it as a leading hub for targeted sequencing applications.
Key Players
• Agilent Technologies Inc.
• BGI Group
• Dnastar Inc.
• Eurofins Genomics LLC (Eurofins Scientific SE)
• F. Hoffmann-La Roche Ltd
• Illumina Inc.
• Integrated DNA Technologies, Inc. (Danaher Corporation)
• Macrogen Inc
• Oxford Nanopore Technologies plc
• PacBio
• Pieriandx
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request for Customization: https://www.imarcgroup.com/request?type=report&id=12570&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
